Wednesday, July 8, 2026

Drug profile · INN

melphalan hydrochloride

melphalan hydrochloride (MELPHALAN HYDROCHLORIDE) is a dna inhibitor. Route of administration: intra-arterial. Current US regulatory status: approved.

FDA: approved
US status approved
Patents linked 0
Pipeline programs 2
News articles 0
Drug details — melphalan hydrochloride
US status
approved
Class
Route
INTRA-ARTERIAL
Patents
0
Programs
2
Data quality
0.84

Quick answer

melphalan hydrochloride (MELPHALAN HYDROCHLORIDE) is a dna inhibitor. Route of administration: intra-arterial. Current US regulatory status: approved.

Key facts

INN melphalan hydrochloride
Brand MELPHALAN HYDROCHLORIDE
Mechanism DNA inhibitor
Target DNA
Route INTRA-ARTERIAL
Formulation INJECTABLE

Mechanism of action

DNA inhibitor

Primary target: DNA

Approval history

Authority Status Date
FDA approved

Pipeline programs

  1. IC 2011-05 Phase 2 · George Institute for · Retinoblastoma
  2. melphalan hydrochloride for injection Approved · CASI Pharmaceuticals · Multiple Myeloma

Related & competitor drugs

  1. acyclovir Human herpesvirus 1 DNA polymerase inhibitor
  2. acyclovir sodium Human herpesvirus 1 DNA polymerase inhibitor
  3. azacitidine Antineoplastic and immunomodulating agents (L01)
  4. bleomycin sulfate DNA inhibitor
  5. busulfan Antineoplastic and immunomodulating agents (L01)
  6. capecitabine Antineoplastic and immunomodulating agents (L01)

Frequently asked questions

What is melphalan hydrochloride?

melphalan hydrochloride (MELPHALAN HYDROCHLORIDE) is a dna inhibitor. Route of administration: intra-arterial. Current US regulatory status: approved.

What is the brand name for melphalan hydrochloride?

MELPHALAN HYDROCHLORIDE is a marketed brand name for melphalan hydrochloride. Check FDA Drugs@FDA for the current US label holder and prescribing information.

What is the US approval status of melphalan hydrochloride?

melphalan hydrochloride has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.